Tocilizumab is a humanized anti-IL6R monoclonal antibody belonging to the IgG1 class that has shown considerable success in the treatment of chronic inflammatory disease [172], but has not previously been used in the treatment of CKD or associated cardiovascular complications. This evidence concerns the gene IL6R and chronic kidney disease.